Status:
COMPLETED
Evaluation of Levemir® for the Treatment of Type 1 and 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
Brief Summary
This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.
Eligibility Criteria
Inclusion
- Type 1 diabetes
- Type 2 diabetes
- Candidates of use of a basal insulin as part of their diabetes regimen
Exclusion
- Unwilling to adhere to therapy or follow up
- Pregnancy
Key Trial Info
Start Date :
May 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2008
Estimated Enrollment :
3637 Patients enrolled
Trial Details
Trial ID
NCT00655044
Start Date
May 1 2007
End Date
January 1 2008
Last Update
October 28 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Moscow, Russia, 119330